Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Current Assets (2022 - 2026)

Kura Oncology has reported Current Assets over the past 5 years, most recently at $623.8 million for Q1 2026.

  • Quarterly Current Assets fell 13.87% to $623.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $623.8 million through Mar 2026, down 13.87% year-over-year, with the annual reading at $708.7 million for FY2025, 4.86% down from the prior year.
  • Current Assets was $623.8 million for Q1 2026 at Kura Oncology, down from $708.7 million in the prior quarter.
  • Over five years, Current Assets peaked at $744.8 million in Q4 2024 and troughed at $416.4 million in Q1 2023.
  • The 5-year median for Current Assets is $518.8 million (2024), against an average of $558.9 million.
  • Year-over-year, Current Assets surged 72.22% in 2024 and then fell 13.87% in 2026.
  • A 5-year view of Current Assets shows it stood at $446.4 million in 2022, then fell by 3.12% to $432.5 million in 2023, then soared by 72.22% to $744.8 million in 2024, then dropped by 4.86% to $708.7 million in 2025, then decreased by 11.98% to $623.8 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Current Assets are $623.8 million (Q1 2026), $708.7 million (Q4 2025), and $620.7 million (Q3 2025).